retatrutide type 2 diabetes phase 2 results 2024 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished The Effect of Retatrutide on

The inclusion criteria included being diagnosed with IBS and suffering abdominal pain or discomfort

Dietary interventions form a cornerstone of IBS management: General dietary advice : Regular meal patterns, adequate hydration (8 glasses of fluid daily), limiting caffeine and alcohol, and reducing fatty or spicy foods Fibre modification : Soluble fibre (such as ispaghula/psyllium) may help, whilst insoluble fibre (bran) can worsen symptoms Low FODMAP diet : A structured elimination and reintroduction protocol, supervised by a registered dietitian, can identify specific carbohydrate triggers Probiotics : Certain strains may provide benefit, though evidence varies Pharmacological treatments are tailored to predominant symptoms: For IBS-D : Loperamide (antimotility agent) for diarrhoea

The recommendations, published in the medical journal JAMA, emphasize that these medications alone are not a solution to treating the global obesity epidemic

Start with a short online questionnaire and, if appropriate, a video or message-based visit with a licensed clinician

This change, effective as of February 21, 2025, impacts compounding pharmacies that had been producing off-brand versions during the shortage